ARAMON Trial: Darolutamide Monotherapy and Testosterone Levels in Biochemically Recurrent Prostate Cancer – Andrew Laccetti
Zach Klaassen discusses the ARAMON trial with Andrew Laccetti, which focuses on the impact of enzalutamide and darolutamide on testosterone levels in patients with high-risk nonmetastatic hormone-sensitive prostate cancer. Dr. Laccetti emphasizes the critical need for treatments that not only enhance cancer outcomes but also minimize side effects and improve quality of life for men undergoing…